Jan. 27 at 5:38 PM
$RANI Great News!! -
$11 this year: Rani Therapeutics Holdings Inc., a clinical-stage biotech company focused on the oral delivery of biologic drugs, has released a new corporate presentation outlining recent developments in its platform technology. The company’s RaniPill device is designed to deliver liquid drug formulations with a capacity of 200 µL (20–40 mg, dependent on drug concentration) and has been tested across 19 different molecules, including antibodies, peptides, and large proteins. According to the presentation, over 7,000 capsules have been evaluated in vitro and in vivo, including a 60-day GLP study with no clinical findings and three completed Phase 1 studies.The RaniPill capsule has been administered to 146 human subjects,and selected pharmacokinetic and pharmacodynamic data suggest comparable bioavailability to subcutaneous injection in preclinical and clinical studies.The internal pipeline focuses on obesity, rare diseases,and immunology, with more than 400 patents
